MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Friday, August 12, 2011

Encouraging Data on Daclizumab


Biogen Idec (BIIB - Analyst Report) and Abbott Labs (ABT -Analyst Report) recently presented positive top-line data on their multiple sclerosis candidate, daclizumab. Biogen and Abbott Labs presented data from a phase IIb study – SELECT.


The global, randomized, double-blind, placebo-controlled, one-year, dose-ranging study was conducted to evaluate the safety and efficacy of daclizumab in 600 patients with relapsing-remitting multiple sclerosis (RRMS).


Two doses (150 mg or 300 mg every four weeks) of daclizumab were evaluated. Results showed that daclizumab reduced the annualized relapse rate by 54% in the 150 mg dose and 50% in the 300 mg dose arm compared to placebo.


Key secondary endpoints were also achieved by the candidate. The study also investigated daclizumab’s effect on disability progression as measured by the expanded disability status scale (EDSS) as a tertiary endpoint. Results showed that daclizumab reduced the risk of sustained disability progression at one year by 57% and 43% in the 150 mg and 300 mg dose arms, respectively. Biogen and Abbott Labs are currently analyzing the data further and expect to present detailed results at an upcoming medical meeting


Read More



..
===========================================================
Remain CURRENT with Multiple Sclerosis news  and information, 
when registered at our  MS Views and News website
.
.Providing You with 'MS Views and News', is what we do 
.
On the 4th Wednesday of each month  
Listen-to StuMSRadio.com at 8pm eastern time.
Each month will feature various guests to be interviewed
Call-in to have (5) minutes of airtime.
Speak about your MS or ask questions 
.
Your donation will Help us to educate

"MS Views and News" is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service 
.. All contributions are tax deductible to the fullest extent allowed by law 
.===========================================================
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

A global collaboration of scientists has identified 29 new genetic variants associated with MS

In the largest MS genetics study ever undertaken, a global collaboration of scientists has identified 29 new genetic variants associated with MS, and confirmed 23 others previously associated with the disease, verifying a major role for the immune system in the development of MS. The study involved nearly 10,000 people with MS and more than 17,000 controls without MS, and was funded by the Wellcome Trust, the National Institutes of Health, the National MS Society and many other organizations. Some 250 investigators of the International MS Genetics Consortium and the Wellcome Trust Case Control Consortium 2 participated in the study, published in the August 11, 2011 issue of Nature (2011;476[7359]:214-219). The results are now to be confirmed and expanded in an independent, second large-scale set of cases with a research grant from the National MS Society.


Click here to continue reading this article


..
===========================================================
Remain CURRENT with Multiple Sclerosis news  and information, 
when registered at our  MS Views and News website
.
.Providing You with 'MS Views and News', is what we do 
.
On the 4th Wednesday of each month  
Listen-to StuMSRadio.com at 8pm eastern time.
Each month will feature various guests to be interviewed
Call-in to have (5) minutes of airtime.
Speak about your MS or ask questions 
.
Your donation will Help us to educate

"MS Views and News" is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service 
.. All contributions are tax deductible to the fullest extent allowed by law 
.===========================================================
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

National MS Society names a new President and CEO


August 10, 2011 -
The board of directors of the National MS Society is pleased to have the honor to announce that effective October 1, Cyndi Zagieboylo will become the National MS Society’s new President and CEO.
Selecting the best candidate to lead the National MS Society is one of the most important duties that the national board has as volunteer leaders. We knew that we were looking for someone who could build on the strengths and extraordinary successes that we have together achieved. Someone who could bring together people from across the MS movement to fuel the necessary growth and innovation needed to realize a world free of MS. And I am pleased to say that we have found this person in Cyndi.
With more than 25-years’ experience at the National MS Society, Cyndi began her career at what was then called the Massachusetts chapter as a director of support services where she worked directly with people with MS, healthcare professionals and the community. From there, she focused on developing programs and services in the southeast and after that became an area director for the northeast where she worked on fund development, financial analysis, strategic planning and mission delivery as well as board member engagement.
As vice president for chapter programs she shifted her focus nationwide to vastly improve the strength of the chapter structure for the Society to better benefit people with MS. In this role she focused on ensuring the Society grew to be a strong unified and mission-focused organization, she helped establish the IRC call center, implemented the chapter certification standards program and developed several key processes for chapter support that remain in place today. As chief field services officer, her most current position, Cyndi’s role in the establishment of our regions was critical as she drove the process to align territories and hired our regional executive vice presidents. Further, she played a key role in establishing our 2011 through 2015 strategic response as a member of the core strategy and implementation team.
“Cyndi knows the MS Society inside and out and is perfectly positioned to become the National MS Society’s next CEO. Her 25-plus-year career at the Society and her vast experience from chapter to regional to national leadership demonstrates her deep knowledge of how this organization functions. Further, her strategic thinking and results-driven track record speak to her strength as a leader,” said Tom Kuhn, national board chair and search committee member.

Continue Reading

===========================================================
Remain CURRENT with Multiple Sclerosis news  and information, 
when registered at our  MS Views and News website
.
.Providing You with 'MS Views and News', is what we do 
.
On the 4th Wednesday of each month  
Listen-to StuMSRadio.com at 8pm eastern time.
Each month will feature various guests to be interviewed
Call-in to have (5) minutes of airtime.
Speak about your MS or ask questions 
.
Your donation will Help us to educate

"MS Views and News" is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service 
.. All contributions are tax deductible to the fullest extent allowed by law 
.===========================================================
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

Thursday, August 11, 2011

29 New Genetic Variants Linked To Multiple Sclerosis Discovered

August 10, 2011


Scientists around the world have discovered 29 new genetic variants associated with MS (multiple sclerosis). They say their findings should help researchers develop new treatments that specifically target areas of the patient's immune system. They published their study in the journal Nature.

The study was done by several researchers from around the world and was led by the Universities of Oxford and Cambridge, in England. The authors say this is the largest study yet into genes and MS.

This new discovery means that scientists now have over 57 genetic clues to MS.

Genes only play a part in MS risk. Other factors, such as vitamin D levels and viral exposure are also believed to play a role. We know that the further somebody is from the equator, the higher his/her risk is (vitamin D from sunlight may be a factor).

The authors explained that T-cells and interleukins appear to play a major role in the development of MS. T-cells are a type of white blood cell that set off an immune response. Interleukins are chemicals that stimulate the activities and growth of certain kinds of white blood cells.

Co-author, Alastair Compston, from Cambridge University, said:

"We have implicated genes that are highly relevant to the actions of those drugs. It is now clear that multiple sclerosis is primarily an immunological disease. This is the way to nail this disease and get on top of it."


Click here to continue reading

===========================================================
Remain CURRENT with Multiple Sclerosis news  and information, 
when registered at our  MS Views and News website
.
.Providing You with 'MS Views and News', is what we do 
.
On the 4th Wednesday of each month  
Listen-to StuMSRadio.com at 8pm eastern time.
Each month will feature various guests to be interviewed
Call-in to have (5) minutes of airtime.
Speak about your MS or ask questions 
.
Your donation will Help us to educate

"MS Views and News" is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service 
.. All contributions are tax deductible to the fullest extent allowed by law 
.===========================================================
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.